XML 49 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
 Three Months Ended March 31
 20252024
Operating Expenses:
Research and development by significant expense:
  BOLSTER trial$788 $1,270 
  ASCEND trial21 44 
  Chemistry, manufacturing and controls220 655 
  Clinical department1,156 1,133 
  Other (1)
417 139 
Research and development2,602 3,241 
General and administrative by significant expense:
  Corporate1,144 1,132 
  Investor relations/public relations/communications331 285 
  Finance629 580 
  Legal224 671 
  Business development127 172 
  Share based compensation expense404 368 
  Other (2)
386 152 
General and administrative3,245 3,360 
Operating loss(5,847)(6,601)
Other income, net161 402 
Benefit from income taxes(962)(798)
Net loss$(4,724)$(5,401)
Cash and marketable securities$25,833 $43,349 
 (1) Included in Other are the GBM study, FORTIFIDE study and research
     oncology expenses
 (2) Included in Other are facilities expense, human resource
     and information technology expenses